Loading…
Hikal (HIKAL)₹225.40+2.18%Pharmaceuticals
Hikal is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a ROCE of 4.0% against a peer median of 5.0%, and latest-quarter sales growth of 6.0% against a peer median of 33.0%. By market cap it is #5 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shukra Pharmaceuticals | 3,618 | 110.9 | 36.9 | 28.9 | 0.06 | 0.0 | 57 | 22 | 379.2 | 1,191.1 | vs HIKAL |
| Unichem Laboratories | 3,584 | 11.7 | 4.0 | 3.2 | 0.18 | 0.0 | 2,200 | 253 | 20.0 | — | vs HIKAL |
| Solara Active Pharma Sciences | 3,143 | 91.9 | 5.0 | −0.1 | 0.41 | 0.0 | 1,374 | −7 | 32.8 | — | vs HIKAL |
| Ind-Swift Laboratories | 3,037 | 36.1 | 5.0 | 4.0 | 0.01 | 0.0 | 649 | 43 | 51.1 | 325.2 | vs HIKAL |
| Hikal | 2,772 | — | 4.0 | 2.9 | 0.57 | 0.3 | 1,714 | −49 | 6.0 | — | — |
| Dishman Carbogen Amcis | 2,616 | 162.2 | 3.0 | 1.6 | 0.46 | 0.0 | 2,927 | 97 | −4.3 | −352.0 | vs HIKAL |
| Fredun Pharmaceuticals | 2,507 | 55.0 | 21.1 | 15.7 | 0.80 | 0.0 | 637 | 33 | 89.9 | 85.7 | vs HIKAL |
| Sakar Healthcare | 2,284 | 53.4 | 12.0 | 10.0 | 0.13 | 0.0 | 251 | 30 | 49.9 | 119.8 | vs HIKAL |
| Sai Parenterals | 2,237 | 156.2 | 5.0 | 4.9 | 0.96 | 0.0 | 382 | 14 | 435.6 | 455.2 | vs HIKAL |
| Panacea Biotec | 2,206 | — | −2.0 | −2.4 | 0.03 | 0.0 | 641 | −7 | 19.5 | −44.3 | vs HIKAL |
| Beta Drugs | 2,089 | 39.0 | 19.0 | 18.9 | 0.11 | 0.0 | 384 | 41 | 33.0 | 58.3 | vs HIKAL |
| Peer median | 2,616 | 55.0 | 5.0 | 4.0 | 0.18 | 0.0 | 641 | 30 | 33.0 | 102.7 |
Listed companies closest to Hikal in Pharmaceuticals include Shukra Pharmaceuticals, Unichem Laboratories, Solara Active Pharma Sciences, Ind-Swift Laboratories, Dishman Carbogen Amcis, Fredun Pharmaceuticals, Sakar Healthcare, Sai Parenterals.
Shukra Pharmaceuticals, with a market cap of ₹3,618 Cr.
Hikal's return on capital employed is 4.0%, below the peer median of 5.0%.